Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2023-02-27 00:00:00 ET · period of report 2023-02-23 · accession 0000899243-23-006296 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-27 | 2023-02-23 | LGND | Reardon Andrew | See Remarks | A - Grant | $0.00 | +5,668 | 16.6K | +52% | $0 |
| D | 2023-02-27 | 2023-02-23 | LGND | Reardon Andrew | See Remarks | A - Grant | $0.00 | +15.4K | 15.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-23 | A | A | 5,668 | $0.00 | 16,608 | D | — | — | (F1) Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three equal annual installments on February 15, 2024; February 15, 2025; and February 15, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2023-02-23 | A | A | 15,393 | $0.00 | 15,393 | D | $75.09 · — to 2033-02-23 | 15,393 Common Stock | (F2) Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from February 23, 2023, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after February 23, 2023 and the remaining stock options vesting in 42 equal monthly installments thereafter. |